cjc-1295 without dac and ipamorelin / Blend CJC-1295 (no DAC) + Ipamorelin

While early attempts to develop selective mAChR and nAChR agonists provided important preliminary findings, these compounds have ultimately failed in clinical development due to a lack of true subtype selectivity and subsequent dose-limiting adverse effects

Possible Side Effects 5-Amino-1MQ has been explored in laboratory and experimental research settings, and observations in some research contexts have included: Injection-site irritation or discomfort Temporary redness or swelling Headaches Nausea Fatigue or temporary energy-related variability Restlessness or stimulation-related observations Appetite-related changes Gastrointestinal discomfort Responses and tolerability observations may vary depending on: Experimental conditions Dosage ranges Protocol duration Administration frequency Concurrent compounds Individual sensitivity Higher-frequency or higher-range experimental protocols may increase the likelihood of tolerability-related observations in some research models

The wealth of preclinical data suggests it holds immense promise, and it's our job to provide the highest-quality version of this tool so that researchers can continue to push the boundaries of science and potentially uncover new ways to address debilitating conditions

Q2 The acne scar on the back has become black like a stain

Yes, but always do a patch test first